Zinker et al. reported that PTP1B antisense oligonucleotides (ASOs) could reduce PTP1B protein expression and could be used as potential therapeutics in the treatment of type 2 diabetes and obesity [8]. This evidence concerns the gene PTPN1 and obesity due to melanocortin 4 receptor deficiency.